Qiagen (QGEN) said Tuesday it plans to launch three new sample preparation instruments, QIAsymphony Connect, QIAsprint Connect, and QIAmini, between 2025 and 2026 to expand its automated sample preparation portfolio.
QIAsymphony Connect, expected to begin a phased launch in 2025, can process up to 96 samples per run and is designed for workflows including pathogen nucleic acid extraction, liquid biopsy, oncology, genomics, and clinical research. It features enhanced automation, digital connectivity, and integration with the QIAsphere cloud-based platform.
QIAsprint Connect, targeted for 2026, is aimed at high-throughput labs and has demonstrated the ability to process up to 192 samples per run with less than 30 minutes of hands-on time, supporting daily volumes of up to 600 samples. It accommodates a broad range of sample types, including plant, microbial, soil, stool, and human tissues.
Also slated for 2026, QIAmini is designed for low-throughput labs, offering a lower-cost entry point into automation with scalability for small batch workflows.
Shares of Qiagen were down 1.3% in recent trading.
Price: 41.78, Change: -0.55, Percent Change: -1.29
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。